Patents Assigned to Bioscience, Inc.
  • Wound or skin treatment devices and methods
    Patent number: 9844470
    Abstract: Devices, kits and methods described herein include skin treatments with a book-like packaging, applicator and/or tensioning device used to apply a dressing to a subject. The packaging, applicator and/or tensioning device is used to apply and/or maintain a strain in an elastic dressing, and has a first support, a second support, and a primary bending region therebetween, the primary bending region comprising a primary bending axis, with the dressing attached to the first and second supports of the device.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: December 19, 2017
    Assignee: Neodyne Biosciences, Inc.
    Inventors: Jasper Jackson, John A. Zepeda, Adam C. French, Darren G. Doud, Geoffrey C. Gurtner, Brett A. Follmer, William R. Beasley, Paul Yock, Keiichiro Ichiryu, Manuel A. Cardona Pamplona, Tor C. Krog, Kemal Levi
  • BACTERIAL EPIGENOMIC ANALYSIS
    Publication number: 20170356028
    Abstract: Provided herein are systems and methods for determining the epigenetic sequences and signatures of bacteria, methods of characterizing bacteria based thereon, and methods of use thereof.
    Type: Application
    Filed: October 22, 2015
    Publication date: December 14, 2017
    Applicant: bis Biosciences, Inc.
    Inventor: Stanley Motley
  • TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20170354697
    Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.
    Type: Application
    Filed: June 22, 2017
    Publication date: December 14, 2017
    Applicant: Vedanta Biosciences, Inc.
    Inventors: Jessica Schneider, Yun-Gi Kim, Bernat Olle, Shilpa Reddy, Jason Norman, Juan Patarroyo
  • Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
    Patent number: 9841425
    Abstract: Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: December 12, 2017
    Assignee: Monogram Biosciences, Inc.
    Inventors: Douglas Richman, Mary T Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
  • Treatment of thrombocytopenia using orally administered interferon
    Patent number: 9839672
    Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: December 12, 2017
    Assignee: Amarillo Biosciences, Inc.
    Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
  • IMMUNONANOTHERAPEUTICS PROVIDING A TH1-BIASED RESPONSE
    Publication number: 20170349433
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable.
    Type: Application
    Filed: June 22, 2017
    Publication date: December 7, 2017
    Applicant: Selecta Biosciences, Inc.
    Inventors: Grayson B. Lipford, Robert L. Bratzler
  • MICRONEEDLE PATCH CONTAINING HYALURONIC ACID FOR COSMETIC USE
    Publication number: 20170348218
    Abstract: The disclosure provides microneedle patches for delivering hyaluronic acid (“HA”) to skin and methods of using the microneedle patches of the disclosure to maintain and/or improve the appearance of skin.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 7, 2017
    Applicant: Sanova Bioscience Inc
    Inventors: Meichin CHEN, Chiasui CHEN, Bingrong LIU, Zihyao LIN
  • Hydrazinyl-indole compounds and methods for producing a conjugate
    Patent number: 9833515
    Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: December 5, 2017
    Assignee: Redwood Bioscience, Inc.
    Inventors: Romas Alvydas Kudirka, Aaron Edward Albers, Robyn M. Barfield, David Rabuka
  • METHODS, APPARATUSES, AND SYSTEMS FOR ANALYZING MICROORGANISM STRAINS FROM COMPLEX HETEROGENEOUS COMMUNITIES, PREDICTING AND IDENTIFYING FUNCTIONAL RELATIONSHIPS AND INTERACTIONS THEREOF, AND SELECTING AND SYNTHESIZING MICROBIAL ENSEMBLES BASED THEREON
    Publication number: 20170342457
    Abstract: Methods, apparatuses, and systems for screening, analyzing and selecting microorganisms from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and synthesizing microbial ensembles based thereon are disclosed. Methods for identifying and determining the absolute cell count of microorganism types and strains, along with identifying the network relationships between active microorganisms and environmental parameters, are also disclosed.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 30, 2017
    Applicant: Ascus Biosciences, Inc.
    Inventors: Mallory EMBREE, Karsten ZENGLER
  • Fused pyrimidines as inhibitors of P97 complex
    Patent number: 9828363
    Abstract: The present invention is directed to certain fused pyrimidines having a homo or hetero cyclopentyl, cyclohexyl or cycloheptyl ring as the pyrimidine fusion partner; having an amino benzyl or substituted amino benzyl group at the 4 position of the pyrimidine ring; and a 5:6 heterobicyclo ring with at least one N, O or S at the 2 position of the pyrimidine ring. These compounds are useful for treatment of cancer by inhibition of the p97 complex.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: November 28, 2017
    Assignee: Cleave Biosciences, Inc.
    Inventors: Han-Jie Zhou, David Wustrow
  • Devices, methods, systems and kits for selecting skin treatment devices
    Patent number: 9827447
    Abstract: Devices, kits, systems and methods described herein may be for treatment to skin, including but not limited to wound healing, the treatment, amelioration, and/or prevention of scars or keloids. Devices kits, systems and methods described herein may be used to select treatment parameters or devices for treating skin in a zone or region of skin having particular mechanical or other properties.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: November 28, 2017
    Assignee: Neodyne Biosciences, Inc.
    Inventors: Kemal Levi, Jasper Jackson, John A. Zepeda, William R. Beasley, Reinhold H. Dauskardt, Michael T. Longaker
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20170335010
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 23, 2017
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Optimizing Total Energy Delivered in Nanosecond Pulses for Triggering Apoptosis in Cultured Cells
    Publication number: 20170333112
    Abstract: An optimization of electrical characteristics for treatments of tumor or other abnormal cells in culture with sub-microsecond, high-electric field electrical pulses is disclosed. The voltages, pulse widths, and number of pulses are chosen such that the treatment energy is 10-20 J/mL. That is, U=n*?t*V*I/volume is 10-20 J/mL, in which n is the number of pulses, ?t is the duration of each pulse, V is the voltage, I is current, and volume is the area of parallel electrodes times the distance between them. V divided by the distance between the electrodes can be in an effective range of 6 kV/cm to 30 kV/cm, 60 kV/cm, 100 kV/cm, or higher intensities. Rows of needle electrodes, blade electrodes, or other configurations of electrodes can approximate parallel electrodes.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard L. Nuccitelli, Zachary R. Mallon, Amanda H. McDaniel, David J. Danitz, Brian G. Athos, Mark P. Kreis, Darrin R. Uecker, Pamela S. Nuccitelli
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20170333481
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 23, 2017
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Methods and products for producing engineered mammalian cell lines with amplified transgenes
    Patent number: 9822381
    Abstract: Methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification are disclosed. In particular, sequences of interest (e.g., genes encoding biotherapeutic proteins) are inserted proximal to selectable genes in amplifiable loci, and the transformed cells are subjected to selection to induce co-amplification of the selectable gene and the sequence of interest. The invention also relates to meganucleases, vectors and engineered cell lines necessary for performing the methods, to cell lines resulting from the application of the methods, and use of the cell lines to produce protein products of interest.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 21, 2017
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Method for assessing protein identity and stability
    Patent number: 9823255
    Abstract: The present invention relates to methods and other technologies that may be used to determine whether compositions (e.g., pharmaceutical compositions) comprising interleukin-10 molecules (e.g., pegylated interleukin-10) meet particular product-related specifications prior to being administered to a subject for the treatment and/or prevention of the diseases, disorders and conditions, and/or the symptoms thereof, described herein.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: November 21, 2017
    Assignee: ARMO BioSciences, Inc.
    Inventors: John Brian Mumm, Peter Van Vlasselaer
  • PULSE APPLICATOR
    Publication number: 20170326361
    Abstract: The pulse applicator includes a first arm, including a first electrode, a second arm, including a second electrode, and a spacer. The first arm, the spacer, and the second arm are movably connected, and define a gap between the first arm and the second arm. The first electrode, the gap, and the second electrode are selectively alignable, and the first electrode and the second electrode are configured to deliver an electrical field across the gap in response to an electrical pulse received across the first and second electrodes.
    Type: Application
    Filed: May 15, 2017
    Publication date: November 16, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Mark P. Kreis, David J. Danitz, Cameron D. Hinman
  • Methods and compositions for treating pain
    Patent number: 9815838
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: November 14, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen Mcnamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Engineered nucleic acid-targeting nucleic acids
    Patent number: 9816093
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: November 14, 2017
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Engineered nucleic-acid targeting nucleic acids
    Patent number: 9816081
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 14, 2017
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May